LINCOLN — LINCOLN PHARMACEUTICALS Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapHigh Flyer

Annual income statement for LINCOLN PHARMACEUTICALS, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	4,721	5,103	5,805	6,232	6,710
Cost of Revenue
Gross Profit	2,440	2,570	2,891	3,189	3,599
Selling / General / Administrative Expenses
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	3,844	4,298	4,912	5,346	5,878
Operating Profit	877	805	893	886	832
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	959	1,005	1,222	1,092	1,156
Provision for Income Taxes
Net Income After Taxes	694	729	933	823	879
Net Income Before Extraordinary Items
Net Income	694	729	933	823	879
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	694	729	933	823	879
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	34.7	36.5	46.6	41.1	43.9
Dividends per Share